Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19132895 | 0.87 | MAPT (0.36) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL15832231 | 0.85 | RAB9A (0.41) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL15924599 | 0.84 | — | — | |
| SCHEMBL15935021 | 0.80 | GABRA1 (0.41) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL15935395 | 0.76 | CYP11B1 (0.39) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL15837150 | 0.74 | MAPT (0.39) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL15935400 | 0.71 | RAB9A (0.39) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL23176227 | 0.70 | MAPT (0.34) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL15819955 | 0.69 | GABRG2 (0.35) | KDM4E | |
| SCHEMBL15935024 | 0.69 | RAB9A (0.41) | HTTMAPTRAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322056-A1 | Factor IXa Inhibitors | F9, F12, F8 | HTT 1935/4885MAPT 4751/4885RAB9A 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.